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Purpose of the study
To explore the clinical significance of morning ATV
plasma concentrations in HIV+ patients taking drugs at
different day times.
Methods
HIV-infected patients on an ATV-containing cART regi-
men since >2 weeks, with an available ATV concentration
obtained by a validated HPLC-UV (group i) 12 ± 2 hours
(C12 h) and (group ii) 24 ± 2 hours (C24 h) after drug
intake and 24 weeks subsequent virological follow-up,
were retrospectively selected. Patients with genotypic
resistance to ATV were excluded. Virological failure was
defined as HIV-RNA >50 copies/ml after 24 weeks.
Summary of results
A total of 171 plasma samples from 112 patients (56%
males, median age 46 years IQR 40–51) were analyzed.
Median time from ATV initiation was 8.9 months (IQR
1.9–17.2). At ATV dosing, 79.5% of patients had a viral
load <50 copies/ml. Overall, 27 (24.1%) showed virolog-
ical failure at 24 weeks. No significant differences in terms
of virological failures were seen between ritonavir-
boosted and unboosted regimens. Median ATV plasma
concentration was higher in patients using boosted regi-
mens: 1.5 mg/L (IQR 0.58–2.30) vs. 0.27 mg/L (IQR
0.05–1.15), p < 0.01.
C12 h ATV concentrations were measured in 115
instances while C24 h in 56 samples. Median ATV plasma
concentration was significantly higher in group (i) com-
pared to group (ii): 1.5 mg/L (IQR 0.7–2.3) vs. 0.26 mg/L
(IQR 0.07–0.67), p < 0.01. Plasma concentration showed
a high interindividual variability in both groups (co-effi-
cient of variation 83.3% and 146.8%, respectively).
In group (i), ROC curve test provided an ATV concentra-
tion cut-off of 0.23 mg/L to predict virological response at
24 weeks: instances (n = 17) with a C12 h ≤0.23 mg/L
showed virological failure in 41.2%, whereas instances (n
= 98) with a C12 h >0.23 mg/L failed in 16.3% of cases (p
= 0.042). A total of 22.5% (20/89) of patients developed
grade III/IV hyperbilirubinaemia. ATV C12 h correlated
with concomitant unconjugated bilirubin (r = 0.223, p =
0.037). A concentration cut-off predictive of >grade III
total bilirubin toxicity could not be identified. No correla-
tions were identified between C24 h and virologic
response or bilirubinemia.
Conclusion
Identification of an ATV C12 h efficacy threshold can be
useful for the clinical application of morning TDM in
patients receiving ATV at night.
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